Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) received approval from its Data Safety and Monitoring Committee to advance its 177Lu-RAD202 treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE